Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

George Kruse

Psychiatry Bronx, NY Medical Doctor

NPI 1417030289 CMS profile 63975

750 Astor Ave, Bronx, NY 10467

Open in the dashboard

General payments

$1,184,687

1,559 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, George Kruse of Bronx, NY is reported in the CMS Open Payments database as having received $1,184,687 across 1,559 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $310,705 360
2024 General $307,830 385
2023 General $195,693 236
2022 General $191,545 309
2021 General $103,400 127
2020 General $15,808 34
2019 General $59,706 108

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • George Kruse
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to George Kruse were reported at $310,705. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year George Kruse Psychiatry median Middle half National median
2019 $59,706 $184 $59–$605 $163
2020 $15,808 $119 $36–$372 $114
2021 $103,400 $143 $43–$576 $132
2022 $191,545 $153 $50–$590 $149
2023 $195,693 $170 $56–$651 $160
2024 $307,830 $179 $57–$673 $164
2025 $310,705 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alkermes, Inc. $695,347 921 payments
  2. Janssen Pharmaceuticals, Inc $409,258 528 payments
  3. E.R. Squibb & Sons, L.L.C. $79,618 83 payments
  4. Otsuka America Pharmaceutical, Inc. $166 5 payments
  5. Neurocrine Biosciences, Inc. $57 4 payments
  6. Vanda Pharmaceuticals Inc. $40 3 payments
  7. Sunovion Pharmaceuticals Inc. $39 4 payments
  8. Otsuka Pharmaceutical Development & Commercialization, Inc. $31 2 payments
  9. Lundbeck LLC $29 2 payments
  10. Indivior Inc. $27 2 payments
  11. Other $75 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $937,968 385 payments
  2. Travel and Lodging $195,376 705 payments
  3. Food and Beverage $29,811 456 payments
  4. Consulting Fee $21,520 11 payments
  5. Education $12 2 payments
Products named General payments · program years 2019–2025
  1. INVEGA SUSTENNA $408,792 522 payments
  2. INVEGA TRINZA $400,818 434 payments
  3. LYBALVI Cns $384,532 524 payments
  4. LYBALVI Cns $366,051 490 payments
  5. LYBALVI Cns $366,051 490 payments
  6. LYBALVI Cns $366,051 490 payments
  7. ARISTADA Cns $329,297 431 payments
  8. ARISTADA Cns $329,297 431 payments
  9. ARISTADA Cns $329,297 431 payments
  10. ARISTADA Cns $329,297 431 payments
  11. Other $380,033 498 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

480

Median for Psychiatry & Neurology: 100

Drug cost

$7,680

Median for Psychiatry & Neurology: $2,986

Branded share of claims

21.7%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Bupropion Xl Bupropion Hcl Brand 53 $1,157
Sertraline Hcl Generic 33 $766
Oxcarbazepine Generic 16 $757
Clozapine Generic 14 $752
Propranolol Hcl Generic 28 $551
Quetiapine Fumarate Er Quetiapine Fumarate Brand 18 $496
Buspirone Hcl Generic 11 $450
Quetiapine Fumarate Generic 48 $350
Divalproex Sodium Er Divalproex Sodium Brand 12 $327
Venlafaxine Hcl Er Venlafaxine Hcl Brand 21 $313

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LYBALVI
$85,349 — —
INVEGA SUSTENNA
$62,635 — —
INVEGA TRINZA
$60,577 — —
ARISTADA
$51,545 — —
COBENFY
$28,098 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

1,559 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record